Accessibility
Our Company
About Us
Our Team
Board of Directors
Scientific Advisory Board
Contact Us
Our Strategy
Scientific Platform
Therapeutic Areas
Manufacturing
Gene Regulation
Research & Development
Pipeline
Clinical Trials
Posters & Publications
Patients & Families
Commitment to Patients
Inherited Retinal Disease
Parkinson’s Disease
Radiation-Induced Xerostomia
Rare Diseases
Investors & Media
Overview
News Releases
Events & Presentations
Stock Information
Corporate Governance
Financial Information
Investor Resources
Join Our Team
Late-Breaking Phase 1/2 Data Demonstrates Safety Profile of Investigational Gene Therapy Botaretigene Sparoparvovec (AAV-RPGR) and Sustained Vision Improvement in Patients with X-Linked Retinitis Pigmentosa (XLRP)